Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Non-invasive methods for the in vivo detection of hallmarks of Alzheimer's disease can
facilitate the study of the progression of the disease in mouse models and may enable its …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Intracellular deposition of α-synuclein and tau are hallmarks of synucleinopathies and
tauopathies, respectively. Recently, several dye-based imaging probes with selectivity for …

Evidence suggests that increased level/aggregation of β-amyloid (Aβ) peptide, together with
enhanced phosphorylation/aggregation of tau protein, play a critical role in the development …

Amyloid beta peptide is an important biomarker in Alzheimer's disease, with the
amyloidogenic hypothesis as one of the central hypotheses trying to explain this type of …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects memory,
thinking, behavior, and other cognitive functions. Although there is no cure, detecting AD …

The deposition of β-amyloid (Aβ) in the brain is a pathologic hallmark of Alzheimer's disease
(AD), appearing years before the onset of symptoms, and its detection is incorporated into …